

Please type a plus sign (+) inside this box



SUBSTITUTE for PTO/SB/105 (0-00), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

4

Attorney Docket Number

COMPLETE IF KNOWN

Application Number	09/835,699
Filing Date	April 16, 2001
First Named Inventor	Armstrong, et al.
Group Art Unit	1631
Examiner Name	Martinell, James

Sheet

1

of

4

Attorney Docket Number 19258CC

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date Considered

4/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	09/835,699
Filing Date	April 16, 2001
First Named Inventor	Armstrong, et al.
Group Art Unit	1631
Examiner Name	Martinell, James

Sheet

2

of

4

Attorney Docket Number 19258CC

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
✓ AG		Gallichan, W. et al. "Mucosal Immunity and Protection after Intranasal Immunization with Recombinant Adenovirus Expressing Herpes Simplex Virus Glycoprotein B". The Journal of Infe. Disease 1993, Vol. 168, PP. 622-629.
✓ AH		Byars et al. "Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection"; Vaccine 1994, Vol. 12, No. 3, PP. 200-209.
✓ AJ		Straus et al. "Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D Vaccine", J. of Infectious Diseases, Vol 167, PP. 1045-52 (1993).
✓ AJ		Ghiasi et al. "Expression of Seven Herpes Simplex Virus Type 1 Glycoproteins (gB, gC, gD, gE, gG, gH and gI): Comparative Protection against Lethal Challange in Mice"; J. Virology, Apr 1994, PP. 2118-2126.
✓ AK		Wachsman et al. "Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes in glycoprotein D", Vaccine, Vol. 10, No. 7, PP. 447-454. (1992)
✓ AJ		Ghiasi et al. "Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D", Arch. Virol (1991) 121: 163-178.
✓ AM		Burke, "Current developments in herpes simplex virus vaccines", Virology, Vol. 4, 1993, PP. 187-197.
✓ AN		Burke, "Development of a Herpes Simplex Virus Subunit Glycoprotein Vaccine for Prophylactic and Therapeutic Use", Reviews of Infectious Diseases, Vol. 13, Suppl 11, P S906-S911 (1991).
✓ AO		Lasky, "From Virus to Vaccine: Recombinant Mammalian Cell Lines as Substrates for the Production of Herpes Simplex Virus Vaccines", J. of Med. Virology, 31: PP. 59-61 (1990).
✓ AP		Aurelian et al. "Immune Responses to Herpes Simplex Virus in Guinea Pigs (Footpad Model) and Mice Immunized with Vaccinia Virus Recombinants Containing Herpes Simplex Virus Glycoprotein D", Review of Infec. Diseases, Vol. 13, (Suppl 11) S924-934 (1991).
✓ AQ		Rooney et al. "Live Vaccinia Virus Recombinants Expressing Herpes Simplex Virus Genes", Reveiws of Infec. Diseases, Vol. 13 (Suppl 11) p S898-903 (1991).
✓ AR		Ritchie et al. "Passive Transfer of Anti-Herpes Simplex Virus Type 2 Monoclonal and Polyclonal Antibodies Protect Against Herpes Simplex Virus Type 1-induced but not Herpes Simplex Virus Type 2-induced Stromal Keratitis", Invest. Ophthal & Vis. Science, Vol. 34, No. 8, PP. 2460-2468 (1993).
✓ AS		Montgomery et al. "Heterologous and Homologous Protection Against Influenza A by DNA vaccination: Optimization of DNA Vectors", DNA and CELL BIOLOGY, Vol. 12, No. 9, PP. 777-783 (1993).
✓ AT		Ulmer et al. "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein", Science, Vol. 259, PP. 1745-1749 (1993).
✓ AU		Browne et al. "Analysis of protective immune responses to the glycoprotein H-glycoprotein L complex of herpes simplex virus type 1", J. of Gen. Virology, Vo. 74, PP. 2813-2817 (1993).

Examiner Signature

Date Considered

6/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Sheet

3

of

4

COMPLETE IF KNOWN

Application Number	09/835,699
Filing Date	April 16, 2001
First Named Inventor	Armstrong, et al.
Group Art Unit	1631
Examiner Name	Martinell, James

Attorney Docket Number 19258CC

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
X	AY	Stanberry et al. "Vaccination with Recombinant Herpes Simplex Virus Glycoproteins: Protection Against Initial and Recurrent Genital Herpes", Jour. of Infec. Dis., Vol. 155, No. 5, PP. 914-920 (1987).
X	AW	Eisenberg et al. "Synthetic Glycoprotein D-related Peptides Protect Mice against Herpes Simplex Virus Challange", J. of Virology, Vol. 56, No. 3, PP. 1014-1017 (1985).
X	AX	Long et al. "Glycoprotein D Protects Mice Against Lethal Challange with Herpes Simplex Virus Types 1 and 2", Infec. and Immunity, Vol. 37, No. 2, PP. 761-764 (1984).
X	AY	Dix et al. "Use of Monolonal Antibody Directed Against Herpes Simplex Virus Glycoprotein to Protect Mice Against Acute Virus-Induced Neurological Disease", Infection and Immunity, Vol. 34, No. 1, PP. 192-199 (1981).
X	AZ	Stanberry et al. "Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy", Antiviral Res. Vol. 11, PP. 203-214 (1989).
X	AAA	Kino et al. "Immunogenicity of herpes simplex virus glycoprotein gB-1 related protein produced in yeast", Chemo-Sero-Ther. Res. Inst. Japan (1988).
X	AAB	McDermott et al. "Protection of Mice against Lethal Challange with Herpes Simplex Virus...Expressing HSV Glycoprotein B", Virology, Vol. 169, PP. 244-247 (1989).
X	AAC	Schmid et al. "The Role of T cell Immunity in Control of Herpes Simplex Virus", Current Topics in Microbiology and Immunology, Vol. 179, PP. 57-74 (1992).
X	AAD	Banks et al. "Recognition by and in Vitro Induction of Cytotoxic T Lymphocytes against Predicted Epitopes of the Immediate-Early Protein ICP27 of Herpes Simplex Virus", J. of Virology, Vol. 67, No. 1, PP. 613-616 (1993).
X	AAE	Watanabe et al. "Induction of Antibodies to a KV Region by Gene Immunization", J. of Immuno. Vol. 151, PP. 2871-2876 (1993).
X	AAF	Ellis et al. "New Vaccine Technologies", JAMA, Vol. 271, No. 12, PP. 929-931.
X	AAG	Ho et al. "Liposome formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea pigs", Vaccine, Vol. 10, Issue 4, PP. 209-213 (1992).
X	AAH	Friedman, "Progress Toward Human Gene Thereapy", Science, Vol. 259, PP. 1275-1281 (1989).
X	AAI	Edgington, "Turning on Tumor Fighting T-Cells", Bio/Technology, Vol. 11, Oct 1993, PP. 1117-1119 (1993).
X	AAJ	Manickan et al. "Protection against HSV infection by DNA vaccination: plasmid DNA encoding HSV-1 gB protects mice from HSV-1 zosteriform lesions", FASEB Jour. Vol. 9, No. 3 P. A207 and Exper. Biol. 95, Part 1, Atlanta GA, USA (Apr9-13) (1995).

Examiner Signature

Date Considered

4/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant.


Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE</p> <p>STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				COMPLETE IF KNOWN	
				Application Number	09/835,699
				Filing Date	April 16, 2001
				First Named Inventor	Armstrong, et al.
				Group Art Unit	1631
				Examiner Name	Martinell, James
Sheet	4	of	4	Attorney Docket Number	19258CC

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	6/24/03
--------------------	---	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.